SCHEMBL6542115

SCHEMBL6542115

CN(C)CCOc1cc(NS(=O)(=O)c2ccccc2-c2ccc(Cl)cc2)ccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 4/20 0.48
HTR7 P34969 1/20 0.42
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
SLC6A9 P48067 1/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ITGA1 P56199 2/20 0.40
MAPT P10636 2/20 0.40
HTT P42858 2/20 0.40
AR P10275 1/20 0.40
PTGES2 Q9H7Z7 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
MCHR1 Q99705 1/20 0.39
EDNRA P25101 1/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
KMT2A Q03164 1/20 0.39
CDK1 P06493 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6541222 0.92 PTGES2 (0.49) UTS2RHTR7ALDH1A1KDM4ESMN1; SMN2
SCHEMBL6542104 0.85 UTS2R (0.48) UTS2RHTR7SLC6A9ALDH1A1KDM4E
SCHEMBL6542559 0.83 PPARG (0.48) UTS2RALDH1A1ITGA1MAPTHTT
SCHEMBL6542775 0.82 UTS2R (0.52) UTS2RALDH1A1MAPTHTTPTGES2
SCHEMBL6542598 0.81 HTR6 (0.49) UTS2RALDH1A1KDM4ESMN1; SMN2EDNRA
SCHEMBL6542141 0.79 UTS2R (0.49) UTS2RALDH1A1KDM4EMAPTHTT
SCHEMBL6186717 0.78 CACNA1B (0.54) UTS2RALDH1A1MAPTHTTAR
SCHEMBL6541415 0.78 UTS2R (0.48) UTS2RALDH1A1SMN1; SMN2MAPTHTT
SCHEMBL6542576 0.78 UTS2R (0.60) UTS2RALDH1A1SMN1; SMN2MAPTHTT
SCHEMBL6542101 0.78 HSD17B1 (0.50) UTS2RALDH1A1SMN1; SMN2MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1248607-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-10-06 EP claimed
US-20030100580-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-05-29 US claimed
EP-1248607-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-10-16 EP claimed
WO-2001045694-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-28 WO claimed
EP-1248607-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-10-06 EP disclosed
US-20030100580-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-05-29 US disclosed
EP-1248607-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-10-16 EP disclosed
WO-2001045694-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100580-A1 Urotensin-II receptor antagonists UTS2R, TMPRSS4, PLAUR UTS2R 1/4885HTR7 746/4885HSP90AA1 3441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.